Using pharmacological inhibitors of these pathways, we found that the TGFβ-ERK/MEK pathway elicits pro-proliferative effects on ovarian cancer cells, although the TGFβ-ERK/MEK pathway is likely not a single, exclusive, ascites-activated pathway. Here, MAP2K7 is linked to ovarian carcinoma.